Search results
Showing 136 to 150 of 157 results for pembrolizumab
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development [GID-TA10900] Expected publication date: TBC
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)
This guidance has been updated and replaced by NICE technology appraisal guidance 766.
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)
This guidance has been updated and replaced by NICE technology appraisal guidance 531.
This guidance has been updated and replaced by NICE technology appraisal guidance 692.
This guidance has been updated and replaced by NICE technology appraisal guidance 939.
This guidance has been updated and replaced by NICE technology appraisal guidance 770.
This guidance has been updated and replaced by NICE technology appraisal guidance 683.
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
follow-up of people who received pembrolizumab as an adjuvant treatment- who develop advanced disease and receive...
A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.
An estimated 100 people per year with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) following the final draft recommendation from NICE.